And then there is the Turing trick: Martin Shkreli, the CEO of Turing, bought out the sole manufacturer of an old, cheap-but-important generic antibiotic, Daraprim, the best treatment for toxoplasmosis (a lethal infection in immunocompromised patients) and promptly raised the price from $13.50 a tablet to $750. Other manufacturers have shamelessly adopted this low-cost, low-risk, high-profit strategy.